Trial Enrollment Upcoming for GTX-102 Following FDA Activation of Its New Drug Application
GTX-102, a potential treatment for Angelman syndrome, is cleared for clinical trials, thanks to the activation of its investigational new drug (IND) application by the U.S. Food and Drug Administration. Enrollment in an upcoming Phase 1/2 trial is due to begin in the first half of…